Changeflow GovPing Healthcare & Life Sciences Tigecycline ANDA 217477 Tentative Approval Hain...
Routine Notice Added Final

Tigecycline ANDA 217477 Tentative Approval Hainan Poly Pharm

Favicon for www.accessdata.fda.gov FDA Drugs@FDA - New Applications and Actions
Published
Detected
Email

Summary

The FDA granted tentative approval to ANDA 217477 for Tigecycline 50MG/1VIAL Injection submitted by Hainan Poly Pharm. Co., Ltd. The action was recorded on April 23, 2026. Tentative approval means the application meets required FDA standards but cannot receive final approval due to patent or exclusivity issues. Marketing status is listed as None pending resolution.

Published by FDA on accessdata.fda.gov . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

GovPing monitors FDA Drugs@FDA - New Applications and Actions for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 9 changes logged to date.

What changed

The FDA Drugs@FDA database records a tentative approval action for Hainan Poly Pharm Co., Ltd.'s Abbreviated New Drug Application for Tigecycline injection. The drug product contains 50MG TIGECYCLINE per vial in injection form. The approval is currently tentative with no final marketing status.

Affected parties including generic drug manufacturers and pharmaceutical companies should note that tentative approval does not authorize commercial marketing. The applicant cannot launch the product until final approval is granted, typically after relevant patents or exclusivity periods expire.

Archived snapshot

Apr 24, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

*Home | *

Abbreviated New Drug Application (ANDA): 217477
Company: HAINAN POLY PHARM. CO., LTD.
- Email

Drug Name Active Ingredients Strength Dosage Form/Route Marketing Status TE Code RLD RS
TIGECYCLINE TIGECYCLINE 50MG/1VIAL INJECTION None (Tentative Approval) None No No
Original Approvals or Tentative Approvals
Action Date Submission Action Type Submission Classification Review Priority; Orphan Status Letters, Reviews, Labels, Patient Package Insert Notes Url
04/23/2026 ORIG-1 Tentative Approval STANDARD Label is not available on this site.

Get daily alerts for FDA Drugs@FDA - New Applications and Actions

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from FDA.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
FDA
Published
April 23rd, 2026
Instrument
Notice
Branch
Executive
Legal weight
Non-binding
Stage
Final
Change scope
Minor

Who this affects

Applies to
Drug manufacturers Pharmaceutical companies
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Generic drug approval ANDA submission Injectable drug review
Geographic scope
United States US

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Regulatory Affairs
Compliance frameworks
GxP
Topics
Healthcare Intellectual Property

Get alerts for this source

We'll email you when FDA Drugs@FDA - New Applications and Actions publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!